Predictors of an EIR at 28 days after primary SARS-CoV-2 vaccination series in MM and WM
| . | OR (95% CI) . | P value . |
|---|---|---|
| MM | ||
| Age >75 years | 0.17 (0.01-1.49) | .11 |
| Male sex | 1.34 (0.55-3.29) | .54 |
| Non-White race | 1.77 (0.39-9.16) | .51 |
| mRNA-1273 (vs BNT162b2) | 2.86(1.07-7.97) | .03 |
| R-ISS stage III (vs I/II) | 0.53 (0.13-1.93) | .39 |
| IgG isotype (vs non-IgG) | 2.82 (1.13-7.32) | .02 |
| Treatment naïve | 1.12 (0.20-6.45) | 1.00 |
| Current treatment | ||
| IMiD | 1.74 (0.71-4.33) | .22 |
| PI | 0.43 (0.16-1.10) | .06 |
| Anti-CD38 mAb | 0.37 (0.13-0.97) | .03 |
| BCMA CAR-T | 1.11 (0.01-89.4) | 1.00 |
| Corticosteroid | 0.29 (0.11-0.73) | .006 |
| Previous ASCT | 1.59 (0.60-4.27) | .37 |
| CR (vs less than CR) | 1.27 (0.42-3.89) | .80 |
| >1 previous treatment line (vs 0-1) | 0.35 (0.10-1.05) | .07 |
| Hypogammaglobulinemia | 0.04 (0.01-0.25) | .004 |
| IV immunoglobulin within 90 days | 0.29 (0.05-1.24) | .08 |
| ALC ×103/μL | 0.23 (0.09-0.54) | <.001 |
| Pulmonary disease | 1.13 (0.24-5.30) | 1.00 |
| Chronic kidney disease | 1.11 (0.01-89.4) | 1.00 |
| Diabetes | 1.66 (0.41-7.20) | .54 |
| Hypertension | 0.58 (0.23-1.44) | .22 |
| Cardiovascular disease | 1.12 (0.14-8.84) | 1.00 |
| Obesity | 1.87 (0.75-4.71) | .15 |
| Current tobacco use | UTC | UTC |
| WM | ||
| Age >65 years | 2.93 (0.60-19.6) | .18 |
| Male sex | 0.38 (0.06-1.86) | .31 |
| Non-White race | UTC | UTC |
| mRNA-1273 (vs BNT162b2) | 8.82 (1.69-63.4) | .004 |
| MYD88 mutation | 0.63 (0.08-7.83) | .63 |
| CXCR4 mutation | 0.32 (0.01-4.77) | .59 |
| Asymptomatic WM | 7.86 (1.58-46.5) | .01 |
| Treatment naïve | 4.80 (1.03-26.2) | .04 |
| Current BTKi use | 0.11 (0.01-0.85) | .01 |
| Current rituximab use | UTC | .04 |
| Progressive disease | 2.90 (0.34-19.8) | .28 |
| >1 previous treatment line (vs 0-1) | 3.29 (0.51-21.7) | .20 |
| Hypogammaglobulinemia | 1.36 (0.27-9.37) | 1.00 |
| IV immunoglobulin within 90 days | 2.24 (0.16-23.0) | .58 |
| ALC ×103/μL | 0.87 (0.46-1.13) | .48 |
| Pulmonary disease | 1.23 (0.10-9.13) | 1.00 |
| Chronic kidney disease | 0.57 (0.01-5.97) | 1.00 |
| Diabetes | UTC | UTC |
| Hypertension | 0.67 (0.10-3.40) | .73 |
| Cardiovascular disease | 1.23 (0.10-9.13) | 1.00 |
| Obesity | 0.73 (0.01-8.52) | 1.00 |
| Current tobacco use | 0.57 (0.01-5.97) | 1.00 |
| . | OR (95% CI) . | P value . |
|---|---|---|
| MM | ||
| Age >75 years | 0.17 (0.01-1.49) | .11 |
| Male sex | 1.34 (0.55-3.29) | .54 |
| Non-White race | 1.77 (0.39-9.16) | .51 |
| mRNA-1273 (vs BNT162b2) | 2.86(1.07-7.97) | .03 |
| R-ISS stage III (vs I/II) | 0.53 (0.13-1.93) | .39 |
| IgG isotype (vs non-IgG) | 2.82 (1.13-7.32) | .02 |
| Treatment naïve | 1.12 (0.20-6.45) | 1.00 |
| Current treatment | ||
| IMiD | 1.74 (0.71-4.33) | .22 |
| PI | 0.43 (0.16-1.10) | .06 |
| Anti-CD38 mAb | 0.37 (0.13-0.97) | .03 |
| BCMA CAR-T | 1.11 (0.01-89.4) | 1.00 |
| Corticosteroid | 0.29 (0.11-0.73) | .006 |
| Previous ASCT | 1.59 (0.60-4.27) | .37 |
| CR (vs less than CR) | 1.27 (0.42-3.89) | .80 |
| >1 previous treatment line (vs 0-1) | 0.35 (0.10-1.05) | .07 |
| Hypogammaglobulinemia | 0.04 (0.01-0.25) | .004 |
| IV immunoglobulin within 90 days | 0.29 (0.05-1.24) | .08 |
| ALC ×103/μL | 0.23 (0.09-0.54) | <.001 |
| Pulmonary disease | 1.13 (0.24-5.30) | 1.00 |
| Chronic kidney disease | 1.11 (0.01-89.4) | 1.00 |
| Diabetes | 1.66 (0.41-7.20) | .54 |
| Hypertension | 0.58 (0.23-1.44) | .22 |
| Cardiovascular disease | 1.12 (0.14-8.84) | 1.00 |
| Obesity | 1.87 (0.75-4.71) | .15 |
| Current tobacco use | UTC | UTC |
| WM | ||
| Age >65 years | 2.93 (0.60-19.6) | .18 |
| Male sex | 0.38 (0.06-1.86) | .31 |
| Non-White race | UTC | UTC |
| mRNA-1273 (vs BNT162b2) | 8.82 (1.69-63.4) | .004 |
| MYD88 mutation | 0.63 (0.08-7.83) | .63 |
| CXCR4 mutation | 0.32 (0.01-4.77) | .59 |
| Asymptomatic WM | 7.86 (1.58-46.5) | .01 |
| Treatment naïve | 4.80 (1.03-26.2) | .04 |
| Current BTKi use | 0.11 (0.01-0.85) | .01 |
| Current rituximab use | UTC | .04 |
| Progressive disease | 2.90 (0.34-19.8) | .28 |
| >1 previous treatment line (vs 0-1) | 3.29 (0.51-21.7) | .20 |
| Hypogammaglobulinemia | 1.36 (0.27-9.37) | 1.00 |
| IV immunoglobulin within 90 days | 2.24 (0.16-23.0) | .58 |
| ALC ×103/μL | 0.87 (0.46-1.13) | .48 |
| Pulmonary disease | 1.23 (0.10-9.13) | 1.00 |
| Chronic kidney disease | 0.57 (0.01-5.97) | 1.00 |
| Diabetes | UTC | UTC |
| Hypertension | 0.67 (0.10-3.40) | .73 |
| Cardiovascular disease | 1.23 (0.10-9.13) | 1.00 |
| Obesity | 0.73 (0.01-8.52) | 1.00 |
| Current tobacco use | 0.57 (0.01-5.97) | 1.00 |
Values corresponding to P < 0.05 are set in bold.
ALC, absolute lymphocyte count; ASCT, autologous stem cell transplantation; CI, confidence interval; CR, complete response; IMiD, immunomodulatory agent; mAb, monoclonal antibody; OR, odds ratio; PI, proteasome inhibitor; UTC, unable to calculate.